Data / Drug companies / Advanz Pharma (US) Corp.
Advanz Pharma (US) Corp.: 20 products in the FDA NDC directory, labeler code 59212
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Advanz Pharma (US) Corp. (labeler code 59212) lists 20 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 20 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on May 19, 2025.
The request: Watch Advanz Pharma (US) Corp. (FDA labeler code 59212): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 59212
- Products in commercial distribution
- 20
- Packages
- 29
- Finished drugs by generic name
- 10
- Prescription products
- 20
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 3
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- December 30, 1980
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 17 | 85% |
| Other unapproved drugs | 3 | 15% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 20 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Digoxin | 3 | 33 |
| Prednisolone sodium phosphate | 3 | 16 |
| Pilocarpine hydrochloride | 2 | 14 |
| Triamterene | 2 | 4 |
| Zonisamide | 2 | 22 |
| Etonogestrel and ethinyl estradiol | 1 | 6 |
| Hydroxychloroquine sulfate | 1 | 33 |
| Alitretinoin | 1 | 1 |
| Alfuzosin hcl | 1 | 1 |
| Tranylcypromine sulfate | 1 | 3 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 5 | 25% |
| Capsule | 4 | 20% |
| Tablet, film coated | 3 | 15% |
| Tablet, orally disintegrating | 3 | 15% |
| Elixir | 2 | 10% |
| Insert, extended release | 1 | 5% |
| Gel | 1 | 5% |
| Tablet, extended release | 1 | 5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| NuvaRing | 59212-146 | Insert, extended release | New drug applications (NDA) | May 19, 2025 |
| Panretin | 59212-601 | Gel | New drug applications (NDA) | September 10, 2019 |
| Salagen | 59212-775 | Tablet, film coated | New drug applications (NDA) | September 1, 2019 |
| Salagen | 59212-705 | Tablet, film coated | New drug applications (NDA) | September 1, 2019 |
| Plaquenil | 59212-562 | Tablet | New drug applications (NDA) | June 28, 2013 |
| Uroxatral | 59212-200 | Tablet, extended release | New drug applications (NDA) | June 3, 2013 |
| Parnate | 59212-447 | Tablet, film coated | New drug applications (NDA) | January 14, 2013 |
| Lanoxin | 59212-249 | Tablet | New drug applications (NDA) | September 30, 2012 |
| Lanoxin | 59212-242 | Tablet | New drug applications (NDA) | September 30, 2012 |
| Lanoxin | 59212-240 | Tablet | New drug applications (NDA) | September 30, 2012 |
| Orapred ODT | 59212-702 | Tablet, orally disintegrating | New drug applications (NDA) | June 1, 2006 |
| Orapred ODT | 59212-701 | Tablet, orally disintegrating | New drug applications (NDA) | June 1, 2006 |
| Orapred ODT | 59212-700 | Tablet, orally disintegrating | New drug applications (NDA) | June 1, 2006 |
| Zonegran | 59212-681 | Capsule | New drug applications (NDA) | March 27, 2000 |
| Zonegran | 59212-680 | Capsule | New drug applications (NDA) | March 27, 2000 |
| Dyrenium | 59212-002 | Capsule | New drug applications (NDA) | October 1, 1999 |
| Dyrenium | 59212-003 | Capsule | New drug applications (NDA) | January 1, 1999 |
| Donnatal | 59212-425 | Tablet | Other unapproved drugs | December 30, 1980 |
| Donnatal | 59212-423 | Elixir | Other unapproved drugs | December 30, 1980 |
| Donnatal | 59212-422 | Elixir | Other unapproved drugs | December 30, 1980 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.